This paper compares the financial statements of two major pharmaceutical companies — U.S.-based Merck and Switzerland-based Novartis — focusing on the differences between U.S. Generally Accepted Accounting Principles (GAAP) and International Financial Reporting Standards (IFRS). It examines auditing standards, the role of the Sarbanes-Oxley Act, presentation differences on balance sheets and income statements, and the comparability of key financial metrics including revenue, net income, and cash flow over a three-year period. The paper concludes that while the statements are superficially comparable, underlying differences in how results are compiled under each framework require closer scrutiny for meaningful analysis.
The paper demonstrates cross-framework comparative analysis: rather than describing GAAP and IFRS in isolation, it anchors each standard to an actual company filing, then traces how regulatory obligations (such as SOX compliance for a cross-listed foreign issuer) create overlapping requirements. This technique shows how abstract accounting rules produce concrete, observable differences in financial statement layout and reported figures.
The paper opens by identifying each company's applicable accounting framework, then examines their shared auditor and the regulatory reason for that overlap. It proceeds to surface-level presentation differences, evaluates overall comparability, and ends with a quantitative snapshot of revenues and net income supported by a side-by-side financial data table. The conclusion cautions that superficial similarity can mask deeper methodological divergence.
Merck is a U.S.-based company and uses U.S. Generally Accepted Accounting Principles (GAAP) to compile its financial statements. Novartis is based in Switzerland and uses International Financial Reporting Standards (IFRS) to prepare its financial statements. Novartis is permitted to use IFRS as a foreign firm, even though it has a cross-listing on the New York Stock Exchange. Because of its foreign status, it files a Form 20-F rather than the standard Form 10-K, acknowledging that it is a foreign entity operating under foreign accounting practices.
The external auditors for Merck are PricewaterhouseCoopers. They certify that they have followed the standards set by the Public Company Accounting Oversight Board (PCAOB) and have also adhered to the internal control integrated framework established by COSO. The auditor for Novartis is also PricewaterhouseCoopers, applying the same COSO internal control integrative framework and PCAOB standards.
It is noteworthy that both companies share the same auditing firm and use the same auditing standards. This can be explained by the cross-listing of Novartis. Because Novartis is listed in the United States, it is subject to U.S. law, including the Sarbanes-Oxley Act (SOX). Indeed, the CEO and CFO of Novartis are required to sign off on the company's financial statements as part of their obligations under SOX. So while Novartis does not need to use GAAP for its financial reporting, it must still follow the tenets of Sarbanes-Oxley with respect to the use of PCAOB standards.
There are several notable differences in the presentation of these financial statements. With regard to Merck, its statements use an unusual format for GAAP filings — for example, they do not clearly distinguish between cost of goods sold and operating expenses. Novartis, using IFRS, presents its statements with a somewhat different layout. Among the most visible differences is that on the balance sheet, long-term assets are listed above current assets, and equity is listed above liabilities. The income statement, however, does not differ substantially between the two companies.
Overall, these statements are reasonably comparable. There are some internal differences — for example, in how revenue is recognized — but with regard to presentation, they are fairly similar. The way the balance sheet is rendered differs slightly, though the adjustment is not difficult to make. The income statement, for the most part, shows only minor cosmetic differences. On the surface, therefore, it should not be difficult to move between these two statements for comparative purposes.
However, while the statements appear highly comparable superficially, the underlying inputs differ. IFRS and GAAP are not always compatible with respect to how results are tabulated and compiled. Even when the two frameworks produce similar-looking presentations, the numbers can be derived in quite different ways. A student wishing to conduct a serious comparison of these statements would need to examine the differences between the two accounting systems in depth in order to fully understand the figures being analyzed.
Both firms record their statements in U.S. dollars, which aids comparability. Novartis presumably also renders its statements in Swiss francs on its home exchange, which would make direct comparison more difficult.
You’re 61% through this paper. Sign up to read the remaining 2 sections.
Sign Up Now — Instant Access Already a member? Log inAlways verify citation format against your institution’s current style guide requirements.